A study of Methylphenidate and Pharmacogenomic Calibration

Overview

About this study

The purpose of this study is to evaluate the predictive value of a custom designed SNP panel test on overall side effect burden caused by methylphenidate at week 8, as well as treatment response. The measure of overall side effect burden will take into account both the number and severity of side effects.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

6-17 years of age.
Diagnosed with ADHD (any type) based on clinical diagnosis, Vanderbilt ADHD Diagnostic Parent and Teacher13 scores greater than 6, and the Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-KID)14.
Starting new stimulant class medication for ADHD.
Able to take oral medication.
Willing to adhere to the study protocol.
Provide a signed and dated informed consent form (parents) and assent (subjects).
Stated willingness to comply with all study procedures and availability for the duration of the study.

Exclusion Criteria:

History of substance use disorders (including nicotine).
Known intellectual disability (full scale IQ < 70).
Unstable or untreated medical illnesses.
Family history of sudden cardiac death (prior to age 45) or personal history of cardiomyopathy or arrhythmia.
Lifetime history of eating disorders or schizophrenic spectrum disorders
Known allergic reactions to components
Female patients who are pregnant

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Rochester, Minn. Mayo Clinic principal investigator Jyoti Bhagia, M.D.	Closed for enrollment

Mayo Clinic Location

Status

Rochester, Minn.

Mayo Clinic principal investigator

Jyoti Bhagia, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Clinical Trials